Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer

BACKGROUND: HSP90 may be a favorable target for investigational therapy in breast cancer. In fact, the HSP90 inhibitor, 17AAG, currently has entered in phase II clinical trials as an anticancer agent in breast and other tumors. Since HSP90 inhibition leads to global depletion of oncogenic proteins i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zajac, Magdalena, Gomez, Gonzalo, Benitez, Javier, Martínez-Delgado, Beatriz
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959047/
https://www.ncbi.nlm.nih.gov/pubmed/20920318
http://dx.doi.org/10.1186/1755-8794-3-44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959047/
https://www.ncbi.nlm.nih.gov/pubmed/20920318
http://dx.doi.org/10.1186/1755-8794-3-44

Ejemplares similares